Kiniksa Pharmaceuticals International (KNSA) 44th Annual J.P. Morgan Healthcare Conference summary

Key achievements and financial highlights

• Reported 2025 unaudited net revenue of $677.5 million, with 62% year-over-year growth and 2026 guidance of $900–$920 million.

• Cumulative net revenue for ARCALYST in recurrent pericarditis reached $1.5 billion since launch.

• Year-end cash reserves of $414 million support ongoing investment and growth initiatives, with expectations to remain cash flow positive.

• ARCALYST market penetration in multiple recurrence patients increased to 18% by end of 2025, up from 13% in 2024.

• Over 4,150 prescribers, with 29% prescribing to two or more patients, and 325 new prescribers added in Q4 2025.

Commercial execution and market development

• ARCALYST is now positioned as the second-line standard of care after NSAIDs and colchicine, supported by ACC Concise Clinical Guidance.

• Innovative AI-driven field alerts and targeted outreach have expanded prescriber base and patient identification.

• Growth in pericardial disease centers from 2 at launch to 18, with these centers outpacing other sites in ARCALYST prescriptions.

• Real-world evidence from the RESONANCE registry shows ARCALYST adoption is reducing corticosteroid use.

• Promotional and medical affairs teams are focused on disseminating new guidelines and data to drive further adoption.

Pipeline and clinical development

• KPL-387 is in phase 2/3 dose-finding study for recurrent pericarditis, aiming for commercialization in 2028–2029.

• KPL-387 offers monthly dosing via autoinjector, with strong preference from both patients and healthcare professionals.

• Phase 2/3 study includes four arms, targeting optimal dose selection for phase 3; topline data expected in second half of 2026.

• KPL-1161, an Fc-modified IL-1 alpha and beta inhibitor, is planned to enter the clinic by end of 2026.

• Portfolio includes ARCALYST, KPL-387, KPL-1161, and abiprubart, with a focus on cardiovascular and specialty indications.